FluoroPharma Medical is a biopharmaceutical company focused on discovering and developing proprietary PET imaging and products for the evaluation of cardiac disease at the cellular and molecular levels. With licensed technology from the Massachusetts General Hospital in Boston, the company’s focus is on enabling personalized medicine through precision diagnostics to help the medical community more accurately diagnose disease at the earliest stages. For more information, visit the company’s Web site at www.fluoropharma.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below: